List of Afferent Pharmaceuticals patents

List of Afferent Pharmaceuticals patents

List of OnePIN patents

List of Labcyte patents

List of NicOx patents

CEOs of webcam companies

List of companies in Chrysalix Venture Capital's investment portfolio

Patents where

Current Assignee

Name

is

Afferent Pharmaceuticals

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11230532 Pyrimidines and variants thereof, and uses therefor	Patent 11230532 was granted and assigned to Afferent Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	11230532	January 25, 2022
	‌ US Patent 11260056 Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough	Patent 11260056 was granted and assigned to Afferent Pharmaceuticals on March, 2022 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	11260056	March 1, 2022
	‌ US Patent 9284279 Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough	Patent 9284279 was granted and assigned to Afferent Pharmaceuticals on March, 2016 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	9284279	March 15, 2016
	‌ US Patent 10206922 Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough	Patent 10206922 was granted and assigned to Afferent Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	10206922	February 19, 2019
	‌ US Patent 10662162 Pyrimidines and variants thereof, and uses therefor	Patent 10662162 was granted and assigned to Afferent Pharmaceuticals on May, 2020 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	10662162	May 26, 2020
	‌ US Patent 9724346 Substituted pyrimidines for treatment of a cough selected from chronic pathological cough, sub-acute pathological cough, acute pathological cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough	Patent 9724346 was granted and assigned to Afferent Pharmaceuticals on August, 2017 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	9724346	August 8, 2017
	‌ US Patent 10195198 Methods and compositions for treating diseases and conditions	Patent 10195198 was granted and assigned to Afferent Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	10195198	February 5, 2019
	‌ US Patent 10822311 Pyrimidines and variants thereof, and uses therefor		Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	10822311	November 3, 2020
	‌ US Patent 11230533 Crystalline salts and polymorphs of a P2X3 antagonist	Patent 11230533 was granted and assigned to Afferent Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	11230533	January 25, 2022
	‌ US Patent 10676444 Crystalline salts and polymorphs of a P2X3 antagonist		Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	10676444	June 9, 2020
	‌ US Patent 10988460 Substituted pyrazole-pyrimidines, variants thereof, and uses therefore	Patent 10988460 was granted and assigned to Afferent Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	10988460	April 27, 2021
	‌ US Patent 10543211 Methods and compositions for treating diseases and conditions	Patent 10543211 was granted and assigned to Afferent Pharmaceuticals on January, 2020 by the United States Patent and Trademark Office.	Afferent Pharmaceuticals	Afferent Pharmaceuticals		United States Patent and Trademark Office	10543211	January 28, 2020

12 results

0 selected

12 results

0 selected